Scroll Down

  • Home

  • >
  • About Heuron

  • >
  • About us

Our Story

AI for Sustainable Happiness

Our brains have the power to create anything
and also to disrupt anything in our daily lives.
Heuron was established to find faster and more accurate solutions
to the most complex and challenging neurological disorders.
From acute emergencies to neurodegenerative conditions,
we ensure sustainable solutions through innovative AI technology.

Brain disorders should not become
obstacles in our lives.
Everyone should enjoy a beautiful,
fulfilling life.

Brain
New Life,

Together.

Vision
& Mission
Key
Milestones
  • Vision

    Heuron safeguards
    brain health,
    the cornerstone of
    sustainable living
    for you and your loved ones.

  • Mission

    Heuron contributes
    to the diagnosis
    and treatment of
    neurological disorders
    using the power of AI.

Heuron,
an AI healthcare company

led by a neurologist.

Heuron has implemented diagnostic algorithms designed by clinical experts
into AI models, offering rapid and accurate solutions.

  • 2023

    Dec

    Heuron StroCare Suite™ Designated as the 56th Innovative Medical Device

  • Nov

    MFDS Class 2 approval for CT Perfusion SW for Stroke
    (Heuron CTP)

  • Winner of the 2023 Republic of Korea Invention Patent Grand Prize, awarded by the Commissioner of the Korean Intellectual Property Office

  • Oct

    FDA 510k Clearance for Dementia SW
    (Veuron-Brain-pAb3)

  • Jun

    Certified for GDPR, HIPAA, CSA-STAR, ISO27001, ISO27799

  • MFDS Class 3 approval for Stroke SW
    (Heuron StroCare Suite™)

  • Mar

    MFDS Class 3 approval for Stroke SW (ELVO)

  • Selected as an outstanding company by the PoC (Proof of Concept) Program

  • Jan

    MFDS Class 2 approval for Dementia SW (Heuron Brain PET)

  • 2022

    Aug

    Clinical trial with Mass General Brigham (Stroke SW)

  • Jul

    FDA approval for Parkinson’s SW
    Clinical trial with 3 hospitals for Parkinson’s Neuromelanin

  • May

    MFDS Class 3 approval for Stroke SW (ASPECTS)

  • Feb

    FDA approval for Dementia SW

  • Jan

    MFDS Class 3 approval for Stroke SW (ICH)

  • 2021

    Nov

    MDSAP(Medical Device Single Audit Program) Certified

  • Won the Minister of Health and Welfare Award for Health Industry Promotion Health and Medical Technology Commercialization

  • Oct

    CE approval for Parkinson’s SW, Dementia SW, Stroke SW

  • Series C Investment ($11.5M)

  • Apr

    MFDS Class 3 approval for Parkinson’s SW

  • Jan

    FDA approval for Dementia SW

  • 2020

    Dec

    Multi-institute clinical results for Parkinson’s SW

  • Nov

    Appointed as one of the 1000 National Representative of Innovative Company

  • Jul

    Series B Investment ($11.7M)

  • KFDA approval and Break through technology for Parkinson’s SW

  • 2019

    Jul

    Series A Investment ($2.3M)

  • 2017

    2017

    Foundation of Heuron Co., Ltd.

  • 01

    Developed Korea’s first NCCT based comprehensive AI solution to support fast triage for acute stroke.
  • 02

    Innovative MRI based AI solution
    developed to facilitate the diagnosis of
    Parkinson’s disease.
  • 03

    Data labelling process performed by
    experienced neurologists from
    university hospitals.
  • 04

    Segmentation template developed
    based on expert knowledge.
    Learning model with high sensitivity
    and specificity.
  • 05

    Extensive range of global patents in the challenging field of AI in brain imaging.
Our Partners

We collaborate with
world-renowned
medical institutions,
based on our
recognized expertise.

Media Resources

Brain New Life, Together.
At Heuron, we are committed
to the sustainable happiness



for all.

TOP